CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86

Bidirectional signaling along the B7–CTLA-4 coreceptor pathway enables reciprocal conditioning of T cells and dendritic cells. Although T cells can instruct dendritic cells to manifest tolerogenic properties after CTLA-4 engagement of B7, such a B7-mediated signaling is not known to occur in response to CD28. Here we show that mouse dendritic cells were induced by soluble CD28 to express interleukin 6 and interferon-γ. Production of interleukin 6 required B7-1 (CD80), B7-2 (CD86) and p38 mitogen-activated protein kinase and prevented interferon-γ-driven expression of immunosuppressive tryptophan catabolism. In vivo, an adjuvant activity of soluble CD28 was demonstrated as enhanced T cell-mediated immunity to tumor and self peptides and protection against microbial and tumor challenge. Thus, different ligands of B7 can signal dendritic cells to express functionally distinct effector responses.

[1]  R. Medzhitov,et al.  Innate immune recognition: mechanisms and pathways , 2000, Immunological reviews.

[2]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[3]  U. Grohmann,et al.  CD40 Ligation Ablates the Tolerogenic Potential of Lymphoid Dendritic Cells1 , 2001, The Journal of Immunology.

[4]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.

[5]  Roland Lang,et al.  SOCS3 regulates the plasticity of gp130 signaling , 2003, Nature Immunology.

[6]  Jeffrey A. Bluestone,et al.  When ligand becomes receptor—tolerance via B7 signaling on DCs , 2002, Nature Immunology.

[7]  U. Grohmann,et al.  Modulation of tryptophan catabolism by regulatory T cells , 2003, Nature Immunology.

[8]  Pascale G. Charest,et al.  β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Saccani,et al.  Two Waves of Nuclear Factor κb Recruitment to Target Promoters , 2001, The Journal of experimental medicine.

[10]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[11]  J. Johnston,et al.  Matching SOCS with function , 2003, Nature Immunology.

[12]  S. Saccani,et al.  p38-dependent marking of inflammatory genes for increased NF-κB recruitment , 2002, Nature Immunology.

[13]  S. Kondo,et al.  Contribution of the CD28 molecule to allergic and irritant-induced skin reactions in CD28 -/- mice. , 1996, Journal of immunology.

[14]  D. Pardoll,et al.  Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance , 2004, Nature Immunology.

[15]  A. Sharpe,et al.  B7/CD28-Dependent CD4+CD25+ Regulatory T Cells Are Essential Components of the Memory-Protective Immunity to Candida albicans1 , 2002, The Journal of Immunology.

[16]  D. Sansom,et al.  What's the difference between CD80 and CD86? , 2003, Trends in immunology.

[17]  J. Lohr,et al.  The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens , 2003, Nature Immunology.

[18]  U. Grohmann,et al.  Tolerance, DCs and tryptophan: much ado about IDO. , 2003, Trends in immunology.

[19]  K P Lee,et al.  Differential T cell costimulatory requirements in CD28-deficient mice. , 1993, Science.

[20]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[21]  R. Schwartz Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy , 1992, Cell.

[22]  M. Sayegh,et al.  T‐cell costimulatory pathways in allograft rejection and tolerance , 2003, Immunological reviews.

[23]  T. Utsugi,et al.  CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. , 2003, Immunity.

[24]  W. Heath,et al.  Immunity or tolerance? That is the question for dendritic cells , 2001, Nature Immunology.

[25]  F. Fallarino,et al.  B7-1 Engagement of Cytotoxic T Lymphocyte Antigen 4 Inhibits T Cell Activation in the Absence of CD28 , 1998, The Journal of experimental medicine.

[26]  P. Ricciardi-Castagnoli,et al.  Dendritic Cells Discriminate between Yeasts and Hyphae of the Fungus Candida albicans , 2000, The Journal of experimental medicine.

[27]  C. Thompson,et al.  T-cell regulation by CD28 and CTLA-4 , 2001, Nature Reviews Immunology.

[28]  A. Sharpe,et al.  CTLA-4 and T cell activation. , 1999, Current opinion in immunology.

[29]  M. David,et al.  Impaired Development of CD4+ CD25+ Regulatory T Cells in the Absence of STAT1 , 2004, The Journal of experimental medicine.

[30]  J R King,et al.  Modelling of signalling via G-protein coupled receptors: Pathway-dependent agonist potency and efficacy , 2003, Bulletin of mathematical biology.

[31]  U. Grohmann,et al.  Functional Plasticity of Dendritic Cell Subsets as Mediated by CD40 Versus B7 Activation 1 , 2003, The Journal of Immunology.

[32]  U. Grohmann,et al.  Th1 and Th2 Cell Clones to a Poorly Immunogenic Tumor Antigen Initiate CD8+ T Cell-Dependent Tumor Eradication In Vivo1 , 2000, The Journal of Immunology.

[33]  U. Grohmann,et al.  IFN-γ Inhibits Presentation of a Tumor/Self Peptide by CD8α− Dendritic Cells Via Potentiation of the CD8α+ Subset1 , 2000, The Journal of Immunology.

[34]  A. Mantovani,et al.  The Contribution of the Toll-Like/IL-1 Receptor Superfamily to Innate and Adaptive Immunity to Fungal Pathogens In Vivo1 , 2004, The Journal of Immunology.

[35]  C. Uyttenhove,et al.  CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum− or helper peptides in priming for skin test reactivity to a P815AB‐related peptide , 1995, European journal of immunology.

[36]  U. Grohmann,et al.  CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.

[37]  J Louahed,et al.  Interleukin-9 regulates NF-kappaB activity through BCL3 gene induction. , 1999, Blood.

[38]  S. Akira,et al.  IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages , 2003, Nature Immunology.

[39]  C. Uyttenhove,et al.  IL-6 Inhibits the Tolerogenic Function of CD8α+ Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase1 , 2001, The Journal of Immunology.

[40]  Oreste Acuto,et al.  CD28-mediated co-stimulation: a quantitative support for TCR signalling , 2003, Nature Reviews Immunology.

[41]  A. Weiss,et al.  Distinct regions in the CD28 cytoplasmic domain are required for T helper type 2 differentiation , 2004, Nature Immunology.

[42]  J. Renauld,et al.  IL-23 and IL-12 Have Overlapping, but Distinct, Effects on Murine Dendritic Cells1 , 2002, The Journal of Immunology.

[43]  J. Mann,et al.  CD40 Induces Interleukin-6 Gene Transcription in Dendritic Cells , 2002, The Journal of Biological Chemistry.

[44]  P. Puccetti,et al.  A TH1-TH2-like switch in candidiasis: new perspectives for therapy. , 1995, Trends in microbiology.

[45]  P. Linsley,et al.  CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. , 1995, Journal of immunology.

[46]  S. Tafuro,et al.  Progression of autoimmune diabetes driven by avidity maturation of a T-cell population , 2000, Nature.

[47]  L. Romani Immunity to fungal infections , 2004, Nature Reviews Immunology.

[48]  Donald Metcalf,et al.  SOCS3 negatively regulates IL-6 signaling in vivo , 2003, Nature Immunology.

[49]  Jeffrey A. Bluestone,et al.  CD28 Function: A Balance of Costimulatory and Regulatory Signals , 2004, Journal of Clinical Immunology.

[50]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[51]  V. Poli,et al.  Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans , 1996, The Journal of experimental medicine.

[52]  J. Allison,et al.  The emerging role of CTLA-4 as an immune attenuator. , 1997, Immunity.

[53]  P. Linsley,et al.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.

[54]  G. Pawelec Extrathymic T-cell differentiation in vitro , 2004, Nature Reviews Immunology.

[55]  C. Uyttenhove,et al.  Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. , 1996, Journal of immunology.